Neurocrine Biosciences Inc. (NBIX)

100.83
NASDAQ : Health Technology
Prev Close 101.50
Day Low/High 100.49 / 102.50
52 Wk Low/High 64.72 / 125.59
Avg Volume 658.40K
Exchange NASDAQ
Shares Outstanding 91.58M
Market Cap 9.30B
EPS 0.20
P/E Ratio 505.60
Div & Yield N.A. (N.A)
Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.

10 Sectors That Will Profit Big-Time From Oil's Crash

10 Sectors That Will Profit Big-Time From Oil's Crash

Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...

Short Interest In Neurocrine Biosciences Increases 16%

The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 1,118,638 share increase in total short interest for Neurocrine Biosciences, Inc. , to 8,122,994, an increase of 15.97% since 05/31/2017.

Biotech Movers: Inovio, Neurocrine, Alnylam

Biotech Movers: Inovio, Neurocrine, Alnylam

Inovio Pharmaceuticals, Neurocrine Biosciences and Alnylam Pharmaceuticals were among the biotech movers in premarket trading on Wednesday.

Week in Review: Wall Street Sees Red as Geopolitical Issues Dominate, Earnings Begin

Week in Review: Wall Street Sees Red as Geopolitical Issues Dominate, Earnings Begin

Geopolitical concerns dominated market moves as banks kicked off earnings season.

U.S. Markets Close Lower as Wall Street Frets Over Global Turmoil

U.S. Markets Close Lower as Wall Street Frets Over Global Turmoil

Stocks closed lower Wednesday as markets continue to grapple with geopolitical uncertainty.

Wall Street Closes Lower Amid Continued Global Worries

Wall Street Closes Lower Amid Continued Global Worries

Stocks closed lower Wednesday as markets continue to grapple with geopolitical uncertainty.

2 Biotech Pullback Targets

2 Biotech Pullback Targets

Acadia and Neurocrine both have catalysts for growth; buy any weakness.

Stocks Fall as Wall Street Can't Shake Geopolitical Concerns

Stocks Fall as Wall Street Can't Shake Geopolitical Concerns

Stocks are lower on Wednesday as markets continue to grapple with geopolitical uncertainty.

Biotech Movers: Neurocrine Biosciences Leaps on Drug Approval, Synergy Pharma Issued Three Patents

Biotech Movers: Neurocrine Biosciences Leaps on Drug Approval, Synergy Pharma Issued Three Patents

The company's shares were up 24% ahead of market's open on an FDA approval.

Neurocrine Biosciences Snags U.S. Approval for Movement Disorder Drug

Neurocrine Biosciences Snags U.S. Approval for Movement Disorder Drug

The U.S. Food and Drug Administration granted Ingrezza a relatively clean label that does not include a black box safety warning against suicidality or depression.

Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen

Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen

Neurocrine Biosciences, Aralez Pharmaceuticals and Qiagen were among the biotech stock movers in premarket trading on Friday.

Analysts' Actions -- Ford, Intel, Whirlpool, Wynn and More

Analysts' Actions -- Ford, Intel, Whirlpool, Wynn and More

Here are Friday's top research calls, including upgrades for Ford, Intel and Wynn Resorts, and a downgrade for Whirlpool.

Neurocrine Drug Fails to Reduce Tic Severity in Tourette Syndrome Patients

Neurocrine Drug Fails to Reduce Tic Severity in Tourette Syndrome Patients

The same Neurocrine drug, valbenazine, is currently under review at the FDA as a treatment for the movement disorder tardive dyskinesia.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

These 5 Biotech Stocks Are Ready for a Volatility Break

These 5 Biotech Stocks Are Ready for a Volatility Break

The squeeze is on these stocks, and they are poised for volatile moves.

Short Interest In Neurocrine Biosciences Jumps 14%

Short Interest In Neurocrine Biosciences Jumps 14%

The most recent short interest data has been released for the 07/15/2016 settlement date, which shows a 606,250 share increase in total short interest for Neurocrine Biosciences, Inc. , to 4,930,434, an increase of 14.02% since 06/30/2016.

Bearish Bets: Biotech, Energy and Other Stocks that Look Good to Short

NBIX, ZPIN, VLP, NWLI and INFO were all recently downgraded by TheStreet's Quant Ratings.

Biogen Should Either a Buyer or a Seller Be

Biogen Should Either a Buyer or a Seller Be

The company sans CEO Scangos needs to do some type of deal in the coming months.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ESNT, HBHC, HMY, IILG, MYCC, NEWM, PRTY, TOT, VTTI Downgrades: NBIX Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Short Interest In Neurocrine Biosciences Decreases By 30%

Short Interest In Neurocrine Biosciences Decreases By 30%

The most recent short interest data has been released for the 06/30/2016 settlement date, which shows a 1,864,374 share decrease in total short interest for Neurocrine Biosciences, Inc. , to 4,324,184, a decrease of 30.13% since 06/15/2016.

Neurocrine Biosciences (NBIX) Strong On High Relative Volume Today

Neurocrine Biosciences (NBIX) Strong On High Relative Volume Today

Trade-Ideas LLC identified Neurocrine Biosciences (NBIX) as a strong on high relative volume candidate

Insider Trading Alert - NBIX, FRGI And LBAI Traded By Insiders

Insider Trading Alert - NBIX, FRGI And LBAI Traded By Insiders

Stocks with insider trader activity include NBIX, FRGI and LBAI

Xenoport's Cost-Cutting Tactics Lead to Buyout With Hefty Premium

Xenoport's Cost-Cutting Tactics Lead to Buyout With Hefty Premium

The biotechnology company, which makes alcoholism drug Horizant, was acquired by privately held Arbor Pharmaceuticals for $467 million in cash, a price lower than at least one analyst expected.

Strong On High Volume: Neurocrine Biosciences (NBIX)

Strong On High Volume: Neurocrine Biosciences (NBIX)

Trade-Ideas LLC identified Neurocrine Biosciences (NBIX) as a strong on high relative volume candidate

Short Interest Moves 11% Higher For NBIX

Short Interest Moves 11% Higher For NBIX

The most recent short interest data has been released for the 04/29/2016 settlement date, which shows a 692,785 share increase in total short interest for Neurocrine Biosciences, Inc. , to 6,943,712, an increase of 11.08% since 04/15/2016.

'Mad Money' Lightning Round: I'm Taking Starbucks Over Bojangles

'Mad Money' Lightning Round: I'm Taking Starbucks Over Bojangles

Cramer prefers Southwest over JetBlue and is waiting on Boeing.

Jim Cramer's 'Mad Money' Recap: Uncle Sam, Back Off Business!

Jim Cramer's 'Mad Money' Recap: Uncle Sam, Back Off Business!

Cramer says the political rhetoric against Big Business is heading down a dangerous path.

Neurocrine Biosciences (NBIX) Stock Gets ‘Outperform’ Rating at BMO Capital

Neurocrine Biosciences (NBIX) Stock Gets ‘Outperform’ Rating at BMO Capital

Neurocrine Biosciences (NBIX) stock was started with an ‘outperform’ rating and $57 price target at BMO Capital Markets.

J.P. Morgan's 53 Top Stock Picks for 2016

J.P. Morgan's 53 Top Stock Picks for 2016

J.P. Morgan analysts identified the most compelling investments for 2016 across growth, value, income-oriented, short and market-neutral strategies. Below is the list of stocks that made the analysts' top picks.

TheStreet Quant Rating: C+ (Hold)